Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 8, 2009, Pages 484-490

  Shimizu, Chikako ^a   Masuda, Norikazu ^b   Yoshimura, Kenichi ^c   Tsuda, Hitoshi ^b   Mano, Masayuki ^b   Ando, Masashi ^a   Tamura, Kenji ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2 (her2); Neoadjuvant chemotherapy; Pathological response; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE SEQUENCE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68849116539     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp052     Document Type: Article

References (16)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Seshadari R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER2-2/oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-84.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med 2005;353:1629-72.
5. Lazaridis G, Pentheroudakis G, Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008;66:31-41.
6. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: Initial results of a randomized trial in operable breast cancer with HER/2 positive disease. J Clin Oncol 2005;23:3676-85.
7. Chang HR, Slamon D, Prati R, Glaspy J, Pegram M, Kass FC, et al. A phase II study of neoadjuvant docetaxel/carboplatin locally advanced breast cancer: Response and cardiotoxicity. J Clin Oncol 2006; 24(18S):s10515.
8. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-5174.
9. Bear HD, Anderson S, Smith RE, Geyer CE, Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;13:2019-27.
10. Leidtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol 2008;26:1275- 81.
11. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, et al. American Joint Committee on Cancer Tumor-Node-Metastasis Stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005;97:1137-42.
12. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, et al. Biologic markers as predictor of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
13. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005;23:8331-9.
14. Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, et al. Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat 2009;113:307-13.
15. Matsumoto K, Shimizu C, Fujiwara Y. The next step to approaching central nervous system in HER2-positive metastatic breast cancer patients. Asia-Pacific J Clin Oncol 2006;2:6-8.
16. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Meric-Bernstam F, et al. Defining prognosis for women with breast cancer and CNS metastasis by HER2 status. Ann Oncol 2008;19:1242-8.